The common bugs of Enterobacteriacea are responsible for urinary tract infections, abdominal infections and hospital-acquired pneumonia. The resistance to Beta lactam in these dreadful bugs is most frequently due to the genetic expression of beta lactamase enzymes. The growing global concerns of Carbapenem resistant enterobacteriacea-CRE dictate a momentum to implement forcing-functions and prevent further wide spread of this global threat. The definition stated by the Center of Disease Control (CDC) define CRE as resistant to any carbapenem antimicrobial (i.e., minimum inhibitory concentrations-MIC of ≥4 mcg/ml for Doripenem, Meropenem, or Imipenem OR ≥2 mcg/ml for Ertapenem), or documented to produce carbapenemase. CRE is a devastating threat that result in adverse consequences including high mortality rates and expedite transmission in facilities. Therefore, attempts to identify CRE their epidemiology, level of threat, recognition of infected patients and respective interventions are the most deterrent steps in climbing the uphill. The efforts to control the emerging CRE are multifactorial and more or less facility-specific. The interplay of global/regional/local public health, Healthcare facilities, nursing homes and the pharmaceutical industry is highly needed to coordinate the available strategic plans including contact precautions, antibiotic stewardship, communications and call for international collaboration with diverse stakeholders. The epidemiology of CRE encompasses the β-lactamases (such as AmpC and Extended Spectrum β-Lactamases-ESBL) and carbapenemases. The later has been implicated in Klebsiella pneumonia-KPCarbenem resistance (KP Carbapenemase-KPC), New Delhi Metalo- β-Lactamase (NMB), Verona Integron-encoded Metallo- β-Lactamase (VIM, Oxacillinase-48-type carbapenemases (OXA-48), and the Imipenemase (IMP) Metallo-β-lactamase. Recognition of patients colonized or infected with CRE represents the core for respective interventions to prevent and minimize the risk posed by transmission. Healthcare facilities need to have the ability to perform carbapenemase testing and CRE screening tests.

The forcing-functions of hand hygiene and contact precautions should be followed strictly. Limiting the use of devices is significant to prevent further device-associated source of CRE. The role of laboratory in following infection control protocols with immediate notifications is of paramount importance. The use of screening contacts personnel of CRE patients or active surveillance testing are deemed to strengthen the control of CRE. Lastly, the ongoing education of healthcare professional is inevitable to ensure a safety culture and further impact all other factors. There are new carbapenem introduced such as Panipenem/betamipron (not FDA approved) Biapenem and Tebipenem. Tebipenem is a novel broad-spectrum orally-administered carbapenemprodrug form (pivalyl ester) developed in Japan as a replacement drug to combat resistance.

References